Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists
- 25 July 2011
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (32) , 13035-13040
Abstract
The Met receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) play an important role in mediating both tumor progression and tissue regeneration. The N-terminal and first Kringle domains (NK1) of HGF comprise a naturally occurring splice variant that retains the ability to activate the Met receptor. However, NK1 is a weak agonist and is relatively unstable, limiting its therapeutic potential. Here, we engineered NK1 mutants with improved biochemical and biophysical properties that function as Met receptor agonists or antagonists. We first engineered NK1 for increased stability and recombinant expression yield using directed evolution. The NK1 variants isolated from our library screens acted as weak Met receptor antagonists due to a mutation at the NK1 homodimerization interface. We introduced point mutations that restored this NK1 homodimerization interface to create an agonistic ligand, or that further disrupted this interface to create more effective antagonists. The rationally engineered antagonists exhibited melting temperatures up to approximately 64 °C, a 15 °C improvement over antagonists derived from wild-type NK1, and approximately 40-fold improvement in expression yield. Next, we created disulfide-linked NK1 homodimers through introduction of an N-terminal cysteine residue. These covalent dimers exhibited nearly an order of magnitude improved agonistic activity compared to wild-type NK1, approaching the activity of full-length HGF. Moreover, covalent NK1 dimers formed from agonistic or antagonistic monomeric subunits elicited similar activity, further signifying that NK1 dimerization mediates agonistic activity. These engineered NK1 proteins are promising candidates for therapeutic development and will be useful tools for further exploring determinants of Met receptor activation.Keywords
This publication has 39 references indexed in Scilit:
- Stability and CDR Composition Biases Enrich Binder Functionality LandscapesJournal of Molecular Biology, 2010
- Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesisProceedings of the National Academy of Sciences, 2010
- Structural basis for agonism and antagonism of hepatocyte growth factorProceedings of the National Academy of Sciences, 2010
- Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from ApoptosisPLOS ONE, 2008
- A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of MetJournal of Biological Chemistry, 2008
- Engineering the NK1 Fragment of Hepatocyte Growth Factor/Scatter Factor as a MET Receptor AntagonistJournal of Molecular Biology, 2008
- A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonistProceedings of the National Academy of Sciences, 2007
- Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonistProceedings of the National Academy of Sciences, 2007
- Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency 1 1Edited by J. A. WellsJournal of Molecular Biology, 1999
- An Approach to Random Mutagenesis of DNA Using Mixtures of Triphosphate Derivatives of Nucleoside AnaloguesJournal of Molecular Biology, 1996